[Federal Register Volume 61, Number 227 (Friday, November 22, 1996)]
[Notices]
[Page 59476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-30023]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION
[File No. 500-1]


Omnigene Diagnostics, Inc., Order of Suspension of Trading

November 19, 1996.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
OmniGene Diagnostics, Inc. (``ODI''), because of questions regarding 
the accuracy of assertions by ODI, and by others, in documents sent to, 
and statements made to, market-makers of the stock of ODI, other 
broker-dealers, and to investors concerning, among other things, ODI's 
alleged ownership and other rights as to certain patents and 
trademarks, ODI's sales, past and projected, ODI's operations and 
facilities, and the number of freely traded shares of ODI common stock.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed company.
    Therefore, it is ordered, pursuant to Section 12(k) of the 
Securities Exchange Act of 1934, that trading in the above-listed 
company is suspended for the period from 9:30 a.m. EST, November 20, 
1996 through 11:59 p.m. EST, on December 4, 1996.

    By the Commission.
Jonathan G. Katz,
Secretary.
[FR Doc. 96-30023 Filed 11-20-96; 12:41 pm]
BILLING CODE 8010-01-M